



Pursuing better quality in all processes

In recent years, the Sawai Group has achieved rapid growth with the success of upfront investment in production facilities and personnel in anticipation of expanding demand for generic drugs. In fiscal 2021, the Group recorded all-time high revenue despite the impact of a reduced number of medical consultations and other factors due to the spread of COVID-19.

